0 extended 0 RP following neoadjuvant chemohormonal therapy (NCH); primarily 6 months of estramustine phosphate 280 mg bid, along with a LH-RH agonist/antagonist. Our surgical technique was developed to reduce the rates of positive surgical margins. The goal is to approach the muscle layer of the rectum by dissecting the mesorectal fascia and continuing the dissection through the mesorectum until the muscle layer of the rectum is exposed. The procedure was safely performed as a result of good recognition of the structure between the perineal body and the rectal surface. We also performed extended lymphadenectomy if the patients meet two or more of D 0 Amico risk categories RESULTS: Pathological analysis revealed that positive surgical margins were found in only two patients. More than 1 year had elapsed after surgery in 64 of the 84 patients with the median follow-up period of 36.1 months. Among those 64 patients, 12 (18.8%) experienced PSA recurrence (Table 1) . Kaplan-Meier analyses revealed that significant poorer PSA progression-free survival were observed in patients with younger age, higher positive biopsy core ratio, positive extra-prostate extension (EPE), lymph node metastasis, and higher pathological stage (pT3a/b). Multivariate Cox-regression analysis revealed that higher pathological stage (pT3a/b) was the only independent valuable for predicting PSA progression failure (Table 2 ). These 12 cases received salvage androgen deprivation therapy followed-by external beam radiotherapy and showed no progression after the salvage therapies (median follow-up period, 22.9 months after PSA progression).
METHODS: 84 high-risk PCa patients prospectively underwent 0 extended 0 RP following neoadjuvant chemohormonal therapy (NCH); primarily 6 months of estramustine phosphate 280 mg bid, along with a LH-RH agonist/antagonist. Our surgical technique was developed to reduce the rates of positive surgical margins. The goal is to approach the muscle layer of the rectum by dissecting the mesorectal fascia and continuing the dissection through the mesorectum until the muscle layer of the rectum is exposed. The procedure was safely performed as a result of good recognition of the structure between the perineal body and the rectal surface. We also performed extended lymphadenectomy if the patients meet two or more of D 0 Amico risk categories RESULTS: Pathological analysis revealed that positive surgical margins were found in only two patients. More than 1 year had elapsed after surgery in 64 of the 84 patients with the median follow-up period of 36.1 months. Among those 64 patients, 12 (18.8%) experienced PSA recurrence (Table 1) . Kaplan-Meier analyses revealed that significant poorer PSA progression-free survival were observed in patients with younger age, higher positive biopsy core ratio, positive extra-prostate extension (EPE), lymph node metastasis, and higher pathological stage (pT3a/b). Multivariate Cox-regression analysis revealed that higher pathological stage (pT3a/b) was the only independent valuable for predicting PSA progression failure (Table 2 ). These 12 cases received salvage androgen deprivation therapy followed-by external beam radiotherapy and showed no progression after the salvage therapies (median follow-up period, 22.9 months after PSA progression).
CONCLUSIONS: NCH concordant with extended RP is feasible and contributes to negative surgical margins that might provide good cancer control for patients with high-risk PCa. METHODS: A total of 14016 men underwent RP between 2005 and 2013 at a tertiary high-volume center. Standardized questionnaires assessing urinary continence (UC), lower urinary tract symptoms (LUTS), erectile (EF) and bowel (BF) function as well as overall health and quality of life (QoL) were completed annually after RP. Additional data for UC and EF were available at three months after RP. UC was defined as the use of zero or 1-safety pad per 24 hours. General EF was assessed using the IIEF-5 (International Index of erectile function) score. EF was defined as a score of 3 points in the second question of the IIEF-5 questionnaire:
00 When you had erections with sexual stimulation, how often were your erections stiff enough for penetration? 00 LUTS were analyzed according to the ICSmaleSF (International Continence Society Male Short-Form) instrument. For evaluation of BF, occurrence of bloody stools was documented. Overall health and QoL was investigated using the last two questions of the EORTC-30 questionnaire.
RESULTS: Post-RP UC rates at 3-months, 1-year UC and 3-years were 74.4%, 86.9% and 86.8% for all patients and considerably higher compared to the results of the ProtecT trial. Similar, recovery of erectile function was better at all three time points with a 3-months EF recovery rate of 26.6% and a 3-year rate of 45.4%. In patients who were potent prior to RP and had bilateral nerve sparing, EF rates were 60.4% three years after RP. LUTS and occurrence of bloody stools was comparable to the ProtecT trial with a mean voiding score of 1.83% and occurrence of bloody stools in less than 1%. Both, overall health and QoL reached a mean of 5.7 out of a total of 7.0 points.
CONCLUSIONS: Compared to the results of the ProtecT trial, functional outcomes were considerably better for patients undergoing RP in a high-volume center. Although RP is associated with UI and erectile dysfunction, most patients reported very good overall health and QoL one year after RP.
